TB-500 dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg vial reconstituted with 2.5 mL bacteriostatic water gives 2 mg/mL. A 2 mg dose equals 100 units on a U100 insulin syringe. Many users split a 5 mg vial into a 2.5 mg loading dose twice weekly.

   Open tool →
2. 2

   Measure the dose

   Typical TB-500 dose is 2.5 mg (Anecdotal protocols use 2 to 5 mg twice weekly during a 4 to 6 week loading phase, then 2 to 5 mg weekly maintenance). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 2x weekly (anecdotal protocols). Half-life of 2 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Anecdotal protocols run 4 to 6 weeks loading at 2x weekly, then weekly maintenance. No controlled human data to support specific cycling.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: injection-site irritation; fatigue (anecdotal); lethargy in early dosing (anecdotal). Stop or reduce dose if tolerability breaks down.

Why this dose

Sequesters G-actin monomers, modulates cell migration and angiogenesis, and upregulates VEGF and myosin transcription. Promotes endothelial differentiation and stem-cell migration to injury sites in preclinical models.

The typical dose (2.5 mg) reflects Anecdotal protocols use 2 to 5 mg twice weekly during a 4 to 6 week loading phase, then 2 to 5 mg weekly maintenance. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

TB-500 is administered via the subcutaneous or intramuscular routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Half-life note: Plasma half-life of full-length TB4 is short (~2 hours in preclinical models); local tissue effects appear to outlast plasma exposure. PEGylated research variants extend half-life substantially.

Cycling and tolerance

Anecdotal protocols run 4 to 6 weeks loading at 2x weekly, then weekly maintenance. No controlled human data to support specific cycling.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• 17-amino-acid fragment of endogenous Thymosin Beta-4, an actin-sequestering peptide
• Preclinical models show accelerated tendon, ligament, and dermal wound healing
• Equine veterinary use for soft-tissue injury is the most documented real-world application
• Anecdotal human protocols use 2 to 5 mg twice weekly subcutaneously for 4 to 6 weeks
• WADA banned under S2 (peptide hormones, growth factors) since 2018
• No completed phase II or III human RCTs as of 2026; long-term safety unestablished

Side effects and interactions

Common side effects

• injection-site irritation
• fatigue (anecdotal)
• lethargy in early dosing (anecdotal)

Notable interactions

• BPC-157 (minor): Frequently co-administered in anecdotal healing protocols; no controlled interaction data

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full TB-500 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not FDA approved; not scheduled; research-chemical status

Pregnancy

Insufficient data

Legal status

Not FDA approved; research-use-only grey market; banned by WADA

Do not use if

• pregnancy
• active malignancy (theoretical angiogenic concern)
• no established human safety profile

Related research